This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VERV Verve Therapeutics (VERV) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Verve Therapeutics Stock (NASDAQ:VERV) Get Verve Therapeutics alerts:Sign Up Key Stats Today's Range$11.13▼$11.1350-Day Range$10.91▼$11.3852-Week Range$3.89▼$11.41VolumeN/AAverage Volume4.91 million shsMarket Capitalization$992.13 millionP/E RatioN/ADividend YieldN/APrice Target$13.50Consensus RatingHold Company Overview Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Read More Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VERV Stock News HeadlinesGoodbye daily statins? VERVE-102 aims to cut LDL cholesterol in one shotJune 8, 2026 | msn.comBig pharma all-in on gene therapy after obesity successMay 31, 2026 | msn.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.June 18 at 1:00 AM | Porter & Company (Ad)A one-time experimental treatment might control cholesterol for lifeMay 29, 2026 | msn.comLilly says gene editing therapy cut “bad” cholesterol in early-stage trialMay 26, 2026 | seekingalpha.comLilly is looking for its next act beyond the weight-loss boomMay 26, 2026 | msn.comLilly says gene editing therapy cut bad cholesterol in early-stage trialMay 26, 2026 | msn.comLilly advances gene therapy, snaps up vaccine makers. It’s looking beyond weight lossMay 26, 2026 | msn.comSee More Headlines VERV Stock Analysis - Frequently Asked Questions How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) posted its earnings results on Wednesday, May, 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.71) by $0.36. The company earned $32.98 million during the quarter, compared to analysts' expectations of $7.13 million. Verve Therapeutics had a negative net margin of 303.64% and a negative trailing twelve-month return on equity of 35.81%. When did Verve Therapeutics IPO? Verve Therapeutics (VERV) raised $239 million in an initial public offering on Wednesday, June 16th 2021. The company issued 14,035,789 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair served as the underwriters for the IPO. What other stocks do shareholders of Verve Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Verve Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/14/2025Today6/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 VERV's financial health is in the Green zone, according to TradeSmith. VERV has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VERV CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees110Year Founded2018Price Target and Rating Average Price Target for Verve Therapeutics$13.50 High Price Target$13.50 Low Price Target$13.50 Potential Upside/Downside+21.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($2.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$198.71 million Net Margins-303.64% Pretax Margin-303.10% Return on Equity-35.81% Return on Assets-27.57% Debt Debt-to-Equity RatioN/A Current Ratio9.84 Quick Ratio9.84 Sales & Book Value Annual Sales$32.33 million Price / Sales30.69 Cash FlowN/A Price / Cash FlowN/A Book Value$5.83 per share Price / Book1.91Miscellaneous Outstanding Shares89,140,000Free Float71,938,000Market Cap$992.13 million OptionableOptionable Beta2.23 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:VERV) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredHow to play the Biggest IPO in stock market history!SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...InvestPub | SponsoredHopeless About Retirement? Hopeless and Helpless Aren’t the Same ThingYour retirement date didn't move once - it moved slowly, then repeatedly, until the shift felt normal. That's ...Golden Portfolio | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredBUY THIS: Claim a backdoor stake in SpaceXThere may be a way to claim pre-IPO exposure to SpaceX before it ever hits public markets - using a simple tra...Chaikin Analytics | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verve Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
